Patent intelligence · US
US 11618784
Anti-CD47 combination therapy
Anti-CD47 combination therapy
Patent details — US 11618784
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 4, 2023
- Expiration
- Mar 30, 2043
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K31/663
Quick answer
US 11618784 (Anti-CD47 combination therapy) is held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD. Status: granted. Granted Apr 4, 2023. Expires Mar 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K31/663, A61K38/212, A61K39/39558
More from TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 11618784?
US 11618784 (Anti-CD47 combination therapy) is held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD. Status: granted. Granted Apr 4, 2023. Expires Mar 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11618784?
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 11618784 expire?
Our index shows an expiration date of Mar 30, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.